Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.58 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.58 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.58 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.58 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.58 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.58 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.58 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | GABRP | O00591 | 4/20 | 0.54 |
| ▸ | GABRD | O14764 | 4/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045004 | 1.00 | MEN1 (0.58) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL497658 | 1.00 | MEN1 (0.58) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL13988189 | 1.00 | MEN1 (0.58) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL11060164 | 1.00 | MEN1 (0.58) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL11345742 | 1.00 | MEN1 (0.58) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL6044996 | 1.00 | MEN1 (0.58) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL11696291 | 0.90 | MEN1 (0.57) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| Acetic Acid SCHEMBL29519885 | 0.89 | GABRP (0.66) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL23872369 | 0.89 | GABRA1 (0.69) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL598324 | 0.89 | GABRA1 (0.69) | MEN1KMT2AAKR1B10AKR1B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259837-A1 | Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-08 | — | — | US | claimed |
| EP-1776122-A1 | USE OF NON-GLUCOCORTICOID STEROIDS FOR THE TREATMENT OF MUSCULAR DYSTROPHY | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-04-25 | — | — | EP | claimed |
| WO-2006007910-A1 | USE OF NON-GLUCOCORTICOID STEROIDS FOR THE TREATMENT OF MUSCULAR DYSTROPHY | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2006-01-26 | — | — | WO | claimed |
| EP-1618881-A1 | Use of non-glucocorticoid steroids for the treatment of muscular dystrophy | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2006-01-25 | — | — | EP | claimed |
| US-4171352-A | Quantitative evaluation of enteric microbial overgrowth | POLYSCIENCES, INC. (US) | 1979-10-16 | — | — | US | claimed |
| US-20260130889-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIV MARYLAND (US) | 2026-05-14 | — | — | US | disclosed |
| US-12433873-B2 | Microtubule polymerization inhibitor prodrugs and methods of using the same | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4403171-A2 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | University of Maryland, Baltimore (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240099955-A1 | SKINCARE COMPOSITIONS AND METHODS OF USE THEREOF | HTL BIOTECHNOLOGY INNOVATION INC. | 2024-03-28 | — | — | US | disclosed |
| EP-3641741-B1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIV MARYLAND (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4288084-A1 | SKINCARE COMPOSITIONS AND METHODS OF USE THEREOF | Modern Meadow, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230241034-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIV MARYLAND (US) | 2023-08-03 | — | — | US | disclosed |
| EP-0004741-A3 | THIO ETIANIC ACID DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL USE | — | 1979-11-14 | — | — | EP | disclosed |
| EP-0004772-A2 | 4-Halo etianic acids and derivatives thereof, their pharmaceutical use and preparation | SYNTEX (U.S.A.) INC. (US) | 1979-10-17 | — | — | EP | disclosed |
| EP-0004741-A2 | Thio etianic acid derivatives, their preparation and pharmaceutical use | SYNTEX (U.S.A.) INC. (US) | 1979-10-17 | — | — | EP | disclosed |
| EP-0004741-A2 | Thio etianic acid derivatives, their preparation and pharmaceutical use | SYNTEX (U.S.A.) INC. (US) | 1979-10-17 | — | — | EP | disclosed |
| EP-0004741-A2 | Thio etianic acid derivatives, their preparation and pharmaceutical use | SYNTEX (U.S.A.) INC. (US) | 1979-10-17 | — | — | EP | disclosed |
| US-4171352-A | Quantitative evaluation of enteric microbial overgrowth | POLYSCIENCES, INC. (US) | 1979-10-16 | — | — | US | disclosed |
| US-4104285-A | OF NORCHOLANIC ACID, BISNORCHOLANIC ACID, OR ETIOCHOLANIC ACID, STEROIDS, BILE FLOW STIMULATORS, ANTILIPEMIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1978-08-01 | — | — | US | disclosed |
| US-3933791-A | Obtention of digitoxigenin from neriifolin and 2'-acetylneriifolin | SYNTEX (U.S.A.) INC. (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259837-A1 | Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy | UTRN, MTPN, NR3C1 | MEN1 2826/4885KMT2A 4662/4885AKR1B10 2675/4885 |
| US-12433873-B2 | Microtubule polymerization inhibitor prodrugs and methods of using the same | TUBA1C, TUBB3, TUBB | MEN1 2488/4885KMT2A 2394/4885AKR1B10 2391/4885 |
| US-20230241034-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | TUBA1C, TUBB3, TUBB | MEN1 2488/4885KMT2A 2394/4885AKR1B10 2391/4885 |
| US-20260130889-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | TUBB3, TUBB1, TUBB | MEN1 4397/4885KMT2A 3703/4885AKR1B10 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.